1. Is Gland Pharma Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Gland Pharma Ltd is a good quality company.
2. Is Gland Pharma Ltd undervalued or overvalued?
The key valuation ratios of Gland Pharma Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
3. Is Gland Pharma Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gland Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||25.4%||26.1%||16.7%||18.7%||21%||13.7%||16.6%||22%||20.3%||17.8%||-|
|Value Creation Index ⓘ||1.3||1.3||0.5||0.7||0.9||0.2||0.5||1.0||0.8||0.6||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||28.7%||0.3%||35.6%||9.7%||9.5%||26.2%||28.8%||31.5%||27.1%||-|
|Adj EPS ⓘ||134.5||186||129.9||194.4||260.1||197.6||281.9||46||59.2||70.4||62.5|
|YoY Gr. Rt. %||-||38.4%||-30.2%||49.7%||33.8%||-24%||42.6%||-83.7%||28.8%||18.9%||-|
|BVPS (₹) ⓘ||518.6||709||889.6||1,082.3||1,348.7||1,555.6||1,847.1||234.3||359.3||434.9||464.5|
|Adj Net Profit ⓘ||158||219||204||301||403||306||437||712||969||1,157||1,029|
|Cash Flow from Ops. ⓘ||155||130||148||224||476||202||185||701||605||791||-|
|Debt/CF from Ops. ⓘ||0.8||1.4||1.1||0.5||0||0||0||0||0||0||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-6.9%||-23%||-37%||18.9%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||29.8||30.3||18.3||19.6||21.4||13.6||16.6||21.9||20.3||17.7||13.9|
|Op. Profit Mgn % ⓘ||30.4||36.4||31.8||37.3||42.3||33||34.6||36.3||37.6||34.3||31|
|Net Profit Mgn % ⓘ||20.5||22.1||20.5||22.4||27.3||18.9||21.4||27||28||26.3||25.3|
|Debt to Equity ⓘ||0.2||0.2||0.1||0.1||0||0||0||0||0||0||0|
|Working Cap Days ⓘ||141||156||208||192||212||239||262||230||200||211||541|
|Cash Conv. Cycle ⓘ||99||101||130||130||128||121||115||119||123||123||466|
Sales growth is growing at healthy rate in last 3 years 29.12%
Return on Equity has declined versus last 3 years average to 13.90%
Net Profit has been subdued in last 3 years -37.02%
Sales growth is not so good in last 4 quarters at 4.82%
|TTM EPS (₹)||62.5||62.5|
|TTM Sales (₹ Cr.)||4,072||4,068|
|BVPS (₹.) ⓘ||464.5||464.6|
|Reserves (₹ Cr.) ⓘ||7,633||7,635|
|From the Market|
|52 Week Low / High (₹)||1660.00 / 4060.00|
|All Time Low / High (₹)||1660.00 / 4350.00|
|Market Cap (₹ Cr.)||28,357|
|Equity (₹ Cr.)||16.5|
|Face Value (₹)||1|
|Industry PE ⓘ||37.8|
The company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956.
The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. It sells its products primarily under a business to business (B2B) model in many countries including the United States, Europe, Canada, Australia, India and the Rest of the world. It has a consistent compliance track record with a range of regulatory regimes across these markets. It also has an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related sophisticated scientific, technical and regulatory processes. It was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems. It has a professional management team and one of its Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.
Business area of company
The company is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various therapeutic areas and delivery systems. It is present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Its delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. It is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.
Awards, accreditations and recognitions:
Major events and milestones